Does Aleve Show Up on a Drug Test? Employer Guide

Quick answer: No. Aleve (naproxen) is not a target of standard 5-panel or 10-panel urine drug tests, so it should not produce a positive result. Rare cross-reactivity with some immunoassays has been reported, which is why any non-negative screen should be confirmed by lab testing (GC-MS or LC-MS/MS) before action.

• Naproxen is an over-the-counter NSAID, not a drug class on standard workplace panels.
• Instant screens are presumptive; only lab confirmation should drive employment, court or treatment decisions.
• Good protocol (medication disclosure, chain of custody, confirmation) protects you from disputes.

What Aleve is and why it is not on standard panels

Aleve is the brand name for naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID) sold over the counter. According to the National Library of Medicine's MedlinePlus, naproxen is used to relieve pain, inflammation and fever. It is not an opioid, stimulant, cannabinoid or other drug of abuse, so standard panels do not look for it.

A typical 5-panel urine screen detects marijuana metabolite (THC-COOH), cocaine metabolite (benzoylecgonine), opiates, amphetamines and phencyclidine (PCP). A 10-panel adds drugs such as benzodiazepines, barbiturates, methadone, methaqualone and propoxyphene or oxycodone, depending on the configuration. NSAIDs like naproxen, ibuprofen and aspirin are not among them.

What standard tests detect and at what cutoffs

Federally regulated testing follows the HHS Mandatory Guidelines published by SAMHSA, which set initial and confirmatory cutoff concentrations. For urine, the initial test cutoffs in the HHS guidelines include 50 ng/mL for marijuana metabolite, 150 ng/mL for cocaine metabolite, 2,000 ng/mL for codeine/morphine, 25 ng/mL for PCP and 500 ng/mL for amphetamines (SAMHSA, Mandatory Guidelines for Federal Workplace Drug Testing Programs). Non-regulated employers often use the same or similar cutoffs, but check each device's insert for its exact cutoffs.

Can naproxen cause a false positive?

Immunoassay screens rely on antibodies that can occasionally bind to compounds with similar structures. Scientific literature and some manufacturer package inserts note rare reports of naproxen cross-reacting with certain assays, most often cited for barbiturate or cannabinoid immunoassays. These reports are uncommon and vary by manufacturer and lot. Because of this, an instant result should never be treated as final.

Confirmatory testing by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) identifies specific molecules. Naproxen would not be mistaken for THC-COOH or another target analyte at that stage.

How to read a non-negative instant result

1. Read the result within the window stated in the device instructions; do not read late.
2. Treat any line pattern indicating a presumptive positive as unconfirmed.
3. Record the donor's disclosed medications without judging them.
4. Send the specimen, with chain of custody intact, to a laboratory for confirmation.
5. Have a qualified reviewer (for regulated programs, a Medical Review Officer) evaluate confirmed positives.

Choosing the right screening format

Your testing format affects how many presumptive results you must manage. Multi-drug drug test cups collect and screen in one step and suit clinics, courts and probation offices that need a built-in temperature strip and tamper evidence. Drug test dip cards offer a lower-cost option for high-volume settings such as staffing firms and treatment centers. Confirm each product's FDA clearance and CLIA-waived status in its documentation, and match the panel to your policy rather than buying more analytes than you need.

DOT and regulated testing

For safety-sensitive transportation employees, the U.S. Department of Transportation's Office of Drug and Alcohol Policy and Compliance (ODAPC) requires testing under 49 CFR Part 40, with laboratory-based testing, split specimens and MRO review. Instant tests are not a substitute for that process. Over-the-counter naproxen is not a DOT-tested drug, and the DOT panel does not include NSAIDs.

Checklist: handling medication questions in your program

• Write a policy that states the panel, cutoffs and confirmation steps.
• Use a pre-test question that lets donors disclose medications privately, not in front of staff.
• Train collectors to read results at the correct time and document them.
• Never take adverse action based on an unconfirmed screen.
• Keep chain-of-custody forms and lot numbers for every test.
• Route disputed results to a lab and a qualified reviewer.
• Pair testing with employment background screening through a consistent hiring workflow where appropriate.

Frequently asked questions

Does Aleve show up on a standard 5-panel urine test?

No. Naproxen is not a target analyte on a 5-panel test, which looks for THC, cocaine, opiates, amphetamines and PCP.

Can Aleve cause a false positive?

Rarely. Some immunoassays have reported cross-reactivity, so a non-negative screen should be confirmed by GC-MS or LC-MS/MS before any decision.

Do donors need to disclose Aleve before a test?

Disclosure is not typically required for an over-the-counter NSAID, but a confidential medication question helps reviewers if a result needs explanation.

Does Aleve show up on a DOT drug test?

No. The DOT panel under 49 CFR Part 40 does not include NSAIDs, and positive results are verified by a laboratory and Medical Review Officer.

Need help choosing supplies?

American Screening Corp supplies wholesale testing products to clinics, hospitals, treatment centers, courts, labs and employers. Contact our team to match panels and formats to your program.

Sources

• MedlinePlus: Naproxen
• SAMHSA: Workplace Drug Testing
• U.S. DOT: Office of Drug and Alcohol Policy and Compliance

This article is general information, not legal or medical advice.